This review highlights recent advances and ongoing controversies in the etiology, diagnosis, and management of isolated growth hormone deficiency in children, emphasizing the need for long-term safety studies of recombinant human GH.
No takes yet. Share an insight, caveat, or question.
Calls for cautious recombinant GH use in pediatric IGHD; leaves open optimal long-term safety and management strategies.
Alatzoglou et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: